Gilead Sciences’ top person, Daniel O’Day on 5-day treatment course with remdesivir for $2,340 per patient
Remdevisir has become a popular word these days, along with Covid-19, Coronavirus, the city of Wuhan, and for a good reason. The headline in all the news, the pricing of remdevisir, has been flooding the internet, and pretty much the TV.
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
In an ongoing U.S. Phase 1/2 placebo-controlled, observer-blinded clinical trial, nucleoside-modified messenger RNA vaccine candidate (BNT162b1) expressing the SARS-CoV-2 receptor
Health Canada lets certain COVID-19 patients to take NuvOx Pharma’s Oxygen therapeutic in phase II clinical trial (edit)
NuvOx Pharma ensured the continuation of Phase 2 clinical trial of its NanO2 in Covid-19 patients with acute hypoxic respiratory failure, as it got No Objection Letter from Health Canada.
Arya and Immatics’s previouslly announced business combination into combined company called Immatics N.V., has been approved by both companies’ shareholders,
Seattle Genetics’ results from the phase 2 of trial testing tisotumab vedotin to treat patients with relapsed or progressed metastatic cervical cancer, showed clinically meaningful and durable objective responses with a manageable safety profile.
Rocket Pharmaceuticals gets FDA clearance for its gene therapy for Infantile Malignant Osteopetrosis
Rocket Pharmaceuticals has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for RP-L401, its, lentiviral vector (LVV)-based gene therapy for the treatment of Infantile Malignant Osteopetrosis (IMO), a rare, severe monogenic bone resorption disorder.
NanoImaging Services (NIS) said on Thursday that it is opening a new facility in Boston to support its growing customer base requiring cryoEM for drug discovery and vaccine development applications. COVID-19 projects are receiving prioritization.
Piramal Pharma buys solid oral dosage drug product facility in Sellersville, Pennsylvania from G&W Laboratories Inc.
Piramal Enterprises Limited’s (PEL) Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania. The transaction closure is subject to customary preclosing conditions.
UPDATE — Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials
IND Candidates Nominated for the Treatment of Liver Disease and Inflammatory Bowel Disease SOUTH SAN FRANCISCO, Calif., June 19, 2020
Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections
TORONTO, June 19, 2020 (GLOBE NEWSWIRE) — New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence